Afrezza

United States Founded: 2009 • Age: 17 yrs
Provides rapid-acting inhaled insulin for blood sugar control in diabetes patients.

About Afrezza

Afrezza is a Healthcare company based in United States founded in 2009. It provides rapid-acting inhaled insulin for blood sugar control in diabetes patients. It operates on a B2C model. Afrezza offers products and services including Afrezza. Its focus areas include Biotechnology, Drug Delivery, Inhaled Medications and Pharmaceuticals. Its legal entity is MannKind Corporation. Its competitors include MannKind Corp, Impel NeuroPharma and Alexza; 3 of its 3 listed competitors have raised funding.

Company details

MannKind Corporation manufactures Afrezza, a rapid-acting inhaled insulin that lowers blood sugar in about 12 minutes for adults with type 1 or type 2 diabetes. It operates through online consultations and resources, targeting US residents, and offers support like savings cards and FAQs. The company focuses on needle-free delivery and collaborates with healthcare providers for accessibility.

  • Headquarters United States
  • Sectors
    Healthcare
  • Phone
    •••• ••••
  • Website afrezza.com
  • Social Facebook Instagram YouTube
  • Legal Name Mannkind Corporation

Products & Services of Afrezza

Afrezza offers a comprehensive portfolio of products and services, including Afrezza.

Afrezza
Inhaled Insulin

Rapid-acting insulin for controlling blood sugar in diabetes patients.

Apps and channels of Afrezza

its YouTube channel AFREZZA has 834 subscribers and 10 videos.

AFREZZA
YouTube 834 subscribers 10 videos Howto & Style
Open channel

Videos from Afrezza

The most watched videos on Afrezza's YouTube channel, AFREZZA (834 subscribers). Click a video to play it here.

How Afrezza Works
196K views
How to Use Afrezza®
15.8K views
Dosing with Afrezza®
1.5K views
Angela On Using Afrezza® Inhaled Insulin
1.2K views

More on AFREZZA.

Competitors of Afrezza

Afrezza has 3 listed competitors in our database, 3 of them funded. They include MannKind Corp, Impel NeuroPharma and Alexza.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
mannkindcorp.com1991Los Angeles, United States$50M322
Developer of small-molecule drugs
impelnp.com2008Seattle, United States$126.83M158
Intranasal delivery technology for CNS diseases is developed.
alexza.com2000Mountain View, United States$97M72
Developer of products for the treatment of acute and intermittent conditions
Premium access

Detailed competitors of Afrezza

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Afrezza

Websites that share an audience with Afrezza (afrezza.com).

Similar websites

Websites whose visitors overlap most with Afrezza. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
myceqursimplicity.com
100%
59.5KView details
eaglepharmacy.com
100%
37.2K#566,679View details

Top companies in Biopharma Outsourcing & Drug Delivery

3 companies that operate in the same segment as Afrezza (Biopharma Outsourcing & Drug Delivery) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Suite solutions are provided for payers and healthcare providers.
1998Princeton, New Jersey, United StatesUSD 220 MUSD 374.1 M5,666
Wearable insulin infusion systems are developed for diabetes patients.
2000Boston, Massachusetts, United StatesUSD 120.4 MUSD 2.71 B3,900
Developer of small-molecule drugs
1991Los Angeles, California, United StatesUSD 50 MUSD 348.97 M407
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Afrezza

Premium access

Complete news archive for Afrezza

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Afrezza

Afrezza was founded in 2009.

Afrezza is headquartered in United States.

MannKind Corporation manufactures Afrezza, a rapid-acting inhaled insulin that lowers blood sugar in about 12 minutes for adults with type 1 or type 2 diabetes. It operates through online consultations and resources, targeting US residents, and offers support like savings cards and FAQs. The company focuses on needle-free delivery and collaborates with healthcare providers for accessibility.

Afrezza's top competitors include MannKind Corp, Impel NeuroPharma and Alexza.

Afrezza offers Afrezza.

Afrezza operates through Mannkind Corporation.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available